The Trump administration proposed ending a complex system of drug rebates that influence tens of billions of dollars in U.S. pharmaceutical spending, a move that could upend the relationship between drugmakers and pharmacy benefits middlemen. The proposal, a long-awaited part …
from News – Insurance Journal
没有评论:
发表评论